COVID-19-Induced Narcolepsy Type I With Cataplexy: A Short Report.

J Sleep ResMay 29, 2026 (epub)
Case ReportNeurology

Torsten Vinding Merinder, Martin Langeskov-Christensen, Filip Kirov

✦ AI-curated · Sources linked

Case in brief

A 42-year-old healthy female developed excessive daytime sleepiness, cataplexy, and hallucinations three months post-SARS-CoV-2 infection. Polysomnography revealed disturbed sleep patterns, while the multiple sleep latency test indicated a mean latency of 1 minute with REM sleep onset. Low cerebrospinal fluid hypocretin levels confirmed narcolepsy type I. Treatment with methylphenidate and venlafaxine significantly improved her symptoms and daily functioning.

What made this case unusual

This case highlights the onset of narcolepsy type I with cataplexy following COVID-19, contributing to the limited literature on this association.

Diagnostic / clinical pearl

Clinicians should consider narcolepsy type I in patients experiencing persistent fatigue and hypersomnolence after COVID-19, as early diagnosis can lead to effective management.

Why it matters

Understanding the potential neurological sequelae of COVID-19, including narcolepsy, is crucial for timely intervention and improved patient outcomes.

Source

PubMed · PMID 42215284

Published in J Sleep Res. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.